Physician profile
Paul Chappano
NPI 1801854674
$2,609.62
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $145 · 2021: $897 · 2022: $750 · 2023: $341 · 2024: $49.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $290.91 | 2020-2022 | |
| Allergan, INC. | $270.23 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.25 | 2020-2022 | |
| W. L. Gore & Associates, INC. | $190.98 | 2019-2024 | Gore Synecor Biomaterial, Gore Enform Preperitoneal Biomaterial |
| Stryker Corporation | $140.87 | 2022 | |
| Asensus Surgical, INC. | $132.43 | 2019 | |
| Novo Nordisk INC | $122.31 | 2019-2023 | Wegovy |
| Abbvie INC. | $121.96 | 2023 | Strattice Reconstructive Tissue Matrix Bps |
| Heron Therapeutics, INC. | $114.01 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $82.14 | 2019-2022 | |
| Tela Bio, INC. | $68.83 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Intuitive Surgical, INC. | $62.55 | 2023 | Da Vinci Surgical System |
| Portola Pharmaceuticals, LLC | $57.79 | 2019-2020 | |
| Smith+Nephew, INC. | $52.21 | 2019-2024 | Renasys Touch |
| Pacira Pharmaceuticals Incorporated | $50.33 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chappano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.